13,759 Shares in Solventum Co. (NYSE:SOLV) Purchased by Abacus FCF Advisors LLC

Abacus FCF Advisors LLC acquired a new position in Solventum Co. (NYSE:SOLV) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,759 shares of the company’s stock, valued at approximately $909,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Modus Advisors LLC bought a new position in shares of Solventum in the fourth quarter valued at approximately $25,000. Stonebridge Financial Group LLC bought a new position in Solventum in the 4th quarter valued at $26,000. Crews Bank & Trust purchased a new stake in shares of Solventum during the 4th quarter valued at $32,000. Synergy Asset Management LLC bought a new stake in shares of Solventum during the 4th quarter worth $35,000. Finally, Spire Wealth Management purchased a new position in shares of Solventum in the 4th quarter worth about $37,000.

Wall Street Analyst Weigh In

SOLV has been the subject of a number of research analyst reports. The Goldman Sachs Group raised their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. Bank of America raised their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. Wells Fargo & Company upped their price objective on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Piper Sandler increased their price objective on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Finally, Mizuho upped their price target on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, Solventum presently has an average rating of “Hold” and an average price target of $79.86.

Solventum Stock Performance

NYSE:SOLV opened at $63.04 on Wednesday. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The business’s fifty day moving average is $74.76 and its 200 day moving average is $71.78. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The firm has a market cap of $10.91 billion and a price-to-earnings ratio of 22.92.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.